Independent and interactive effects of viral species on early-life lower respiratory tract illness
- PMID: 41015263
- DOI: 10.1016/j.jinf.2025.106616
Independent and interactive effects of viral species on early-life lower respiratory tract illness
Abstract
Objectives: To determine the association between viral species and odds of severe lower respiratory tract illnesses (sLRI) versus upper respiratory illness (URI) among children under 2 years of age.
Methods: Infants (n=2,061) enrolled in the Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory Outcomes were surveilled for respiratory illnesses until age 2 years (March 2020 to April 2024). Nasal swabs from 1,363 illnesses (774 participants) were screened for 21 pathogens.
Results: RSV infections occurred in 23% of sLRIs and increased odds of sLRI vs URI (OR=9.28; 95% CI, 5.43-15.85). Metapneumovirus, parainfluenza, and non-SARS-CoV-2 coronavirus also increased odds of sLRIs, while SARS-CoV-2 was associated with lower risk of sLRIs. Rhinovirus (43%) and bocavirus (16.1%) were commonly detected, but were not associated with sLRI risk. Co-infection with multiple viral species was associated with 2.92-fold greater odds of sLRI (95% CI, 2.05-4.16) compared to single viral species infections. Rhinovirus-bocavirus was the most common co-infection, and interaction between these viruses was associated with increased odds of sLRI.
Conclusions: Diverse viral pathogens drive early-life sLRIs. Some (e.g. RSV and metapneumovirus) have intrinsic propensity to cause sLRIs, while other viruses' lower airway pathogenicity depends on other factors, including co-infection.
Keywords: Coinfection; Infants; Pediatrics; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Rhinovirus.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S. Oh is currently employed by Amgen Inc. M. A. Seibold reports receipt of research funding from Genentech, Medimmune, and Pfizer. D. Sheppard is a scientific founder of Pliant Therapeutics. The rest of the authors declare that they have no relevant conflicts of interest.
Update of
-
Independent and interactive effects of viral species on risk for lower respiratory tract illnesses in early life.medRxiv [Preprint]. 2025 Feb 26:2025.02.25.25322678. doi: 10.1101/2025.02.25.25322678. medRxiv. 2025. Update in: J Infect. 2025 Sep 25:106616. doi: 10.1016/j.jinf.2025.106616. PMID: 40061332 Free PMC article. Updated. Preprint.
LinkOut - more resources
Full Text Sources
Miscellaneous